Goldberg & Goldberg has filed one of the first products liability cases in the country against Abbott Laboratories concerning the drug Humira. Humira is expected to be the world’s biggest selling medication, with estimated 2012 sales of $8.7 billion. Humira is a TNF (tumor necrosis factor) blocker that is used to treat Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Ankylosing Spondylitis and Juvenile Arthiritis, among other conditions. Humira works by binding TNF and reducing pain, inflamation and joint damage that is caused by these conditions. Humira affects the immune system, and because of this, can hurt the bodies ability to fight infections and can cause a whole host of other problems.
Unfortunately, Humira causes neurological problems, opportunistic infections and malignancies. The litigation filed against Abbott claims that Abbott was aware of these problems and failed to warn the users of Humira about the real dangers associated with the drug.
The first trial of a Humira case is now set for April of 2013. Goldberg & Goldberg has taken a lead role in the prosecution of this litigation. If you or a loved one has been injured by the drug Humira, please call us. We would be happy to discuss your potential case with you.